Last reviewed · How we verify
NCT07084181
Fitbit Assessed PS in Colorectal Cancer
trial in Colorectal Cancer (Diagnosis) in 80 participants. Completed in 22 July 2019.
22 July 2019
Quick facts
| Lead sponsor | Fox Chase Cancer Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 15 February 2017 |
| Primary completion | 22 July 2019 |
| Estimated completion | 22 July 2019 |
| Sites | 1 location across United States |
Conditions studied
- Colorectal Cancer (Diagnosis) — all drugs for Colorectal Cancer (Diagnosis) →
Sponsor
Fox Chase Cancer Center — full company profile →
Who can join
18 and older, any sex, with Colorectal Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary Objective To assess the feasibility of activity tracking using Fitbit device in terms of compliance (defined as at least 75% of patients complying with instructions to wear the device, for at least 12 hours a day on at least 3 of the 4 assigned days) in patients undergoing therapy for localized and advanced colorectal cancer. Secondary Objectives * To determine if physician-assessed performance status correlates with FitbitTM assessed physical activity (using active-minutes data). * To correlate baseline physical activity level as assessed by FitbitTM with incidence of grade III or higher toxicities experienced during treatment * To assess correlation between patient reported treatment related toxicities (PRO-CTCAE) and objective physical activity as measured by FitbitTM in patients treated for localized or metastatic cancers treated with chemotherapy * To correlate baseline and interval change in physical activity levels as assessed by FitbitTM with post-surgical outcomes including inpatient length of stay, perioperative complications, post-operative 30-day mortality, and time to adjuvant treatment initiation (in days)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07084181
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer (Diagnosis)
Currently open trials in the same condition.
- NCT07464626 — Virtual vs Physical Art Therapy for Anxiety, Psychological Well-being, and Sleep Quality in Colorectal Cancer Patients · NA · recruiting
- NCT07477522 — Effects of High-Fiber Diet on Gut Microbiota, Metabolism, and Immune Microenvironment in Solid Tumor Patients: A Clinica · Phase 1 · recruiting
- NCT07069556 — ColoSense Post-Approval Study · recruiting
- NCT07087561 — Short-Term Nutritional Enhancement Combined With Health Education in Postoperative Colorectal Cancer Patients: A Randomi · NA · recruiting
- NCT07224854 — Epigenetic Signature for CRC Early Detection · active not recruiting
Other Fox Chase Cancer Center trials
Trials by the same sponsor.
- NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
- NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
- NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
- NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
- NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07084181 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
- Last refreshed: 12 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07084181.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing